Company intelligence / Profile preview

Forcyte Biotechnologies

Los Angeles, California, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Forcyte Biotechnologies is building a preclinical pipeline of small-molecule “mechano-therapeutics” discovered using its FLECS high-throughput mechanobiology platform; programs in fibrosis, lung fibrosis, asthma, and over-active bladder are currently in discovery-to-IND-enabling stages, with no clinical-stage assets disclosed yet.[1][2][4][8][10]

Therapeutic areas: NephrologyImmunologyWomen's HealthCardiovascularDermatologyPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Undisclosed leading pharmaceutical company collaboration on mechanomedicine programs[2]Multiple biopharma company collaborations using the FLECS platform for their projects[1][2]Numerous translational research groups globally using FLECS assay well-plate products and technology[1][8]

Beyond the preview

Go deeper on Forcyte Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forcyte Biotechnologies.

Explore the full profile